Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

LY-2405319 as a potential new treatment for metabolic disorders

June 28, 2013

Zealand Pharma presents ZP-GA-1, a new glucagon analogue

June 27, 2013

NICE recommends dapagliflozin in certain patients with type 2 diabetes

June 27, 2013

Boston College patents new PDE11A inhibitors

June 27, 2013

Bristol-Myers Squibb patents new MGAT2 inhibitors

June 26, 2013

DiaMedica provides update on DM-199 program for type 2 diabetes

June 26, 2013

Researchers from Korea present phase II data for lobeglitazone

June 26, 2013

A novel potent LPL activator improves plasma lipid levels in vivo

June 26, 2013

Amarin reports results from phase I trial of AMR-102

June 25, 2013

Fecal metagenome associated with glucose control in a European cohort

June 25, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...